Ariad Plunges After FDA Places Trials of Inclusig on Hold
This article is for subscribers only.
Ariad Pharmaceuticals Inc. tumbled the most ever after U.S. regulators placed a hold on enrollment in all trials of the company’s approved cancer drug Iclusig because of blood clots among participants.
Ariad dropped 66 percent to $5.83 in the biggest decline since the shares started trading publicly in 1994. The company has declined 70 percent this year.